NCT03869619 REal World Data in LYmphoma and Survival in Adults
| NCT ID | NCT03869619 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hospices Civils de Lyon |
| Condition | Diffuse Large B Lymphoma (DLBCL) |
| Study Type | OBSERVATIONAL |
| Enrollment | 6,000 participants |
| Start Date | 2018-11-14 |
| Primary Completion | 2027-11-14 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 6,000 participants in total. It began in 2018-11-14 with a primary completion date of 2027-11-14.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
REALYSA cohort is a population-based epidemiological platform in real-life for lymphomas designed to enrich prognostic data, by integrating together epidemiological, clinical and biological data. REALYSA is a platform perfectly set up to * Study prognostic factors using integrated epidemiological and biological data (genetics), to better characterize the determinants of refractoriness and relapse in patients with lymphoma, to follow the growing number of survivors and describe median to long-term sequela, second cancer, quality of life (QoL)… * Document treatment effectiveness in real life and observance * Address socio-economical questions
Eligibility Criteria
Inclusion Criteria: * Signature of the consent form for participation in the REALYSA cohort * Aged over 18 at the time of inclusion * Diagnosed with lymphoma in the last 6 months (180 days) * Lymphoma subtype belonging to at least one of the 7 histological subtypes: diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, T-cell lymphoma, Hodgkin's lymphoma, Burkitt lymphoma Exclusion Criteria: * Anti-lymphoma treatment already received (except pre-phase: typically corticosteroids, vincristine, cyclophosphamide, etoposide, alone or in combination) * Documented HIV infection * Any other lymphoma subtype not included in the list in Appendix 1. Of note, are excluded: * Chronic lymphocytic leukemia/small lymphocytic lymphoma * Hairy cell leukemia and variant * Lymphoplasmacytic lymphoma * Waldenström macroglobulinemia * Primary DLBCL of the central nervous system (CNS) * T-cell large granular lymphocytic leukemia * Chronic lymphoproliferative disorder of NK cells * Mycosis fungoides * Sézary syndrome * Primary cutaneous T cell lymphomas (mainly diagnosed and treated by dermatologists) * Post-transplant lymphoproliferative disorders (PTLD)
Contact & Investigator
Hervé Ghesquières, MD
STUDY DIRECTOR
Hospices Civils de Lyon
Frequently Asked Questions
Who can join the NCT03869619 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Diffuse Large B Lymphoma (DLBCL). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03869619 currently recruiting?
Yes, NCT03869619 is actively recruiting participants. Contact the research team at herve.ghesquieres@chu-lyon.fr for enrollment information.
Where is the NCT03869619 trial being conducted?
This trial is being conducted at Arras, France, Besançon, France, Bordeaux, France, Bordeaux, France and 11 additional locations.
Who is sponsoring the NCT03869619 clinical trial?
NCT03869619 is sponsored by Hospices Civils de Lyon. The principal investigator is Hervé Ghesquières, MD at Hospices Civils de Lyon. The trial plans to enroll 6,000 participants.